Showing 3821-3830 of 5773 results for "".
- Actress Kate Walsh Teams Up with Alcon for Dry Eye Campaignhttps://modernod.com/news/actress-kate-walsh-teams-up-with-alcon-for-dry-eye-campaign/2480754/Alcon announced a partnership with actress Kate Walsh, best known for her roles in Grey’s Anatomy and Emily in Paris, to share her journey with dry eye around the launch of its Systane Complete Preservative-Free Lubricant Eye Drops. As part of the new
- AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Diseasehttps://modernod.com/news/axim-biotech-develops-rapid-quantitative-tear-test-for-mmp-9-an-inflammatory-biomarker-of-dry-eye-disease/2480753/AXIM Biotechnologies announced that it has successfully developed a rapid quantitative tear test for MMP-9, an inflammatory biomarker for dry eye disease. "Dry eye disease, though widespread, is under-diagnosed, in part because symptoms do not always
- Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocationhttps://modernod.com/news/alimera-exhibits-continued-growth-and-expansion-with-new-branding-and-office-relocation/2480750/Alimera Sciences announced that the company has launched new corporate branding and moved its global headquarters to a new, state-of-the-art facility. Alimera refreshed its corporate brand for the first time in the company’s two-decade history to better represent its current
- Amydis Appoints Robert N. Weinreb, MD, as First Chair of Scientific Advisory Boardhttps://modernod.com/news/amydis-appoints-robert-n-weinreb-md-as-first-chair-of-scientific-advisory-board/2480742/Amydis announced the appointment of clinician scientist, Robert N. Weinreb, MD, as the First Chair to the Scientific Advisory Board of the company. “Amydis is at the forefront of developing compounds that enable retinal imaging of molecula
- Novartis Receives European Commission Approval of Beovu for Diabetic Macular Edema (DME)https://modernod.com/news/novartis-announces-european-commission-approval-of-beovu-for-diabetic-macular-edema-dme/2480740/Novartis announced that the European Commission (EC) has approved Beovu (brolucizumab) 6 mg for the treatment of visual impairment due to diabetic macular edema (DME). Today’s approval in DME represents the second indication for Beovu granted by the EC, which was first approved for the
- Outlook Therapeutics Submits Biologics License Application to the FDA for ONS-5010 as a Treatment for Wet AMDhttps://modernod.com/news/outlook-therapeutics-submits-biologics-license-application-to-the-fda-for-ons-5010-as-a-treatment-for-wet-amd/2480738/Outlook Therapeutics announced it has submitted its biologics license application (BLA) to the FDA for ONS-5010, an investigational therapy which, if approved, will be branded as Lytenava (bevacizumab-vikg), for the treatment of wet age-related macular degeneration (AMD).&nbs
- Luneau Technology Launches as 'Visionix' to Manufacture and Sell Optovue, Visionix, Briot and Weco Brandshttps://modernod.com/news/luneau-technology-launches-as-visionix-to-manufacture-and-sell-optovue-visionix-briot-and-weco-brands/2480736/Luneau Technology Group recently announced that it will take on 'Visionix' as its official global name beginning March 31, 2022, unveiling a combined booth at Vision Expo East. As mentioned in the recent global announcement, 'Optovue' will transition to a product brand f
- Nova Eye President Appointed to American Glaucoma Society (AGS) Foundation Advisory Boardhttps://modernod.com/news/nova-eye-president-appointed-to-american-glaucoma-society-ags-foundation-advisory-board/2480735/Nova Eye Medical has announced that Joe Bankovich, President of Nova Eye, has been appointed as an industry representative to the American Glaucoma Society Foundation Advisory Board. Established in 2011 and comprising over 1500 members, the American Glaucoma Society Foundation runs
- Study: Dry Eye Disease Signs and Symptoms Significantly Reduced with Ciclosporin A 0.1% Cationic Emulsionhttps://modernod.com/news/study-dry-eye-disease-signs-and-symptoms-significantly-reduced-with-ciclosporin-a-01-cationic-emulsion/2480734/Santen EMEA has announced the results of PERSPECTIVE, a real-world evidence study evaluating the long-term treatment of severe keratitis in adult dry eye disease (DED) patients. The study, which was conducted across 44 ophthalmology clinics in 5 European countries, demonstrated that ciclosporin A
- Graybug Updates its Ophthalmic Pipeline Programshttps://modernod.com/news/graybug-updates-its-ophthalmic-pipeline-programs/2480733/Graybug Vision announced a strategic update on its pipeline programs GB-102 in wet age-related macular degeneration (AMD); GB-401, in primary open-angle glaucoma (POAG); as well as its newly acquired assets in corneal disease (GB-501); inherited retinal diseases (GB-601); and